Search results
Results from the WOW.Com Content Network
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine [1] which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. [2]The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope [3]) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials. [6] As a result, two additional NeuVax trials registered or underway are: (1) a 700 patient Phase 3 trial for FDA approval - not yet recruiting [2] [needs update] and (2) a 300 patient Phase 2 trial studying the combination of ...
Rindopepimut is the epidermal growth factor receptor (EGFR)-derived peptide vaccine to treat glioblastoma multiforme (GBM). The 14-mer peptide is coupled with keyhole limpet hemocyanin (KLH), which can reduce the risk of cancer. [11] E75, GP2, and AE37 are three different HER2/neu-derived single-peptide vaccines to treat breast cancer. HER2/neu ...
Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210. [1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example gp100:280-288(288V ...
Several DC-based cancer vaccines have been developed including DC loaded with, tumor peptides or whole proteins, [6] with tumor-derived mRNA or DNA., [7] DC transduced with viral vectors such as retroviruses, [8] lentiviruses [9] adenoviruses, [10] fowl pox [11] and alphaviruses containing the tumor antigen or gene of interest, whole necrotic ...
A Florida woman is now cancer free and in recovery after receiving a trial vaccine at the Mayo Clinic earlier this year. ... She would receive the vaccine shot several times over a 12-week period ...
The personalized anti-tumor vaccines are made of specific DNA to target mutated cancer genes. The DNA is derived from a patient’s own biopsy of their tumor. Roughly a third of the patients ...
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. [2] The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.